ARTICLE | Finance
With details on lead sialoglycan degrader in place, Palleon raises $100M series B
September 18, 2020 1:04 AM UTC
Having nominated a lead program, identified top indications and sorted out manufacturing, Palleon raised a $100 million series B round to bring its enzymatic sialoglycan degrader to the clinic for ...
BCIQ Company Profiles